Adage Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $113M | Sell |
251,990
-20,484
| -8% | -$9.55M | 0.17% | 116 |
|
|
2025
Q4 | $124M | Sell |
272,474
-210,021
| -44% | -$90.5M | 0.19% | 101 |
|
|
2025
Q3 | $189M | Buy |
482,495
+304,303
| +171% | +$127M | 0.3% | 52 |
|
|
2025
Q2 | $79.3M | Sell |
178,192
-311,475
| -64% | -$144M | 0.13% | 151 |
|
|
2025
Q1 | $237M | Buy |
489,667
+280,428
| +134% | +$131M | 0.44% | 34 |
|
|
2024
Q4 | $84.3M | Sell |
209,239
-137,116
| -40% | -$63.6M | 0.15% | 132 |
|
|
2024
Q3 | $161M | Buy |
346,355
+11,194
| +3% | +$5.38M | 0.28% | 63 |
|
|
2024
Q2 | $157M | Sell |
335,161
-15,095
| -4% | -$6.55M | 0.29% | 59 |
|
|
2024
Q1 | $146M | Buy |
350,256
+50,066
| +17% | +$21.2M | 0.28% | 67 |
|
|
2023
Q4 | $122M | Buy |
300,190
+186
| +0.1% | +$68.7K | 0.25% | 84 |
|
|
2023
Q3 | $104M | Sell |
300,004
-6,029
| -2% | -$2.11M | 0.24% | 98 |
|
|
2023
Q2 | $108M | Sell |
306,033
-32,357
| -10% | -$10.9M | 0.23% | 102 |
|
|
2023
Q1 | $107M | Buy |
338,390
+158,500
| +88% | +$47.5M | 0.24% | 100 |
|
|
2022
Q4 | $51.9M | Sell |
179,890
-157,273
| -47% | -$47.9M | 0.12% | 201 |
|
|
2022
Q3 | $97.6M | Sell |
337,163
-234,867
| -41% | -$67.6M | 0.24% | 98 |
|
|
2022
Q2 | $161M | Sell |
572,030
-221,260
| -28% | -$59.2M | 0.37% | 51 |
|
|
2022
Q1 | $207M | Buy |
793,290
+572,400
| +259% | +$136M | 0.39% | 47 |
|
|
2021
Q4 | $48.5M | Buy |
220,890
+46,930
| +27% | +$9.13M | 0.09% | 234 |
|
|
2021
Q3 | $31.6M | Sell |
173,960
-164,980
| -49% | -$32.2M | 0.06% | 320 |
|
|
2021
Q2 | $68.3M | Sell |
338,940
-548,800
| -62% | -$115M | 0.13% | 165 |
|
|
2021
Q1 | $191M | Buy |
887,740
+205,600
| +30% | +$45.2M | 0.39% | 50 |
|
|
2020
Q4 | $161M | Buy |
682,140
+391,150
| +134% | +$89.7M | 0.35% | 59 |
|
|
2020
Q3 | $79.2M | Sell |
290,990
-108,662
| -27% | -$30M | 0.2% | 109 |
|
|
2020
Q2 | $116M | Sell |
399,652
-511,300
| -56% | -$139M | 0.3% | 72 |
|
|
2020
Q1 | $217M | Buy |
910,952
+101,251
| +13% | +$23.2M | 0.65% | 21 |
|
|
2019
Q4 | $177M | Sell |
809,701
-62,800
| -7% | -$12.7M | 0.44% | 45 |
|
|
2019
Q3 | $148M | Buy |
872,501
+219,360
| +34% | +$38.8M | 0.36% | 62 |
|
|
2019
Q2 | $120M | Buy |
653,141
+208,900
| +47% | +$36.5M | 0.3% | 84 |
|
|
2019
Q1 | $81.7M | Buy |
444,241
+11,729
| +3% | +$2.17M | 0.2% | 126 |
|
|
2018
Q4 | $71.7M | Buy |
432,512
+36,500
| +9% | +$6.32M | 0.2% | 142 |
|
|
2018
Q3 | $76.3M | Sell |
396,012
-464,892
| -54% | -$82.8M | 0.17% | 151 |
|
|
2018
Q2 | $146M | Buy |
860,904
+200,223
| +30% | +$31M | 0.34% | 67 |
|
|
2018
Q1 | $108M | Sell |
660,681
-698,600
| -51% | -$114M | 0.25% | 107 |
|
|
2017
Q4 | $204M | Buy |
1,359,281
+323,100
| +31% | +$47.8M | 0.46% | 50 |
|
|
2017
Q3 | $158M | Buy |
1,036,181
+71,200
| +7% | +$10.7M | 0.38% | 59 |
|
|
2017
Q2 | $124M | Buy |
964,981
+600,319
| +165% | +$72.3M | 0.3% | 80 |
|
|
2017
Q1 | $39.9M | Buy |
364,662
+110,535
| +43% | +$9.73M | 0.1% | 268 |
|
|
2016
Q4 | $18.7M | Sell |
254,127
-321,900
| -56% | -$26.2M | 0.05% | 383 |
|
|
2016
Q3 | $50.2M | Sell |
576,027
-119,800
| -17% | -$11.3M | 0.14% | 200 |
|
|
2016
Q2 | $59.9M | Sell |
695,827
-327,549
| -32% | -$28.3M | 0.16% | 165 |
|
|
2016
Q1 | $81.3M | Sell |
1,023,376
-390,400
| -28% | -$35.3M | 0.22% | 129 |
|
|
2015
Q4 | $178M | Buy |
1,413,776
+515,000
| +57% | +$62.2M | 0.47% | 54 |
|
|
2015
Q3 | $93.6M | Sell |
898,776
-11,000
| -1% | -$1.41M | 0.26% | 103 |
|
|
2015
Q2 | $112M | Sell |
909,776
-520,808
| -36% | -$65.6M | 0.28% | 99 |
|
|
2015
Q1 | $169M | Sell |
1,430,584
-664,548
| -32% | -$79.6M | 0.41% | 57 |
|
|
2014
Q4 | $249M | Sell |
2,095,132
-496,545
| -19% | -$55.9M | 0.61% | 27 |
|
|
2014
Q3 | $291M | Sell |
2,591,677
-375,690
| -13% | -$35.8M | 0.72% | 20 |
|
|
2014
Q2 | $281M | Buy |
2,967,367
+1,309,893
| +79% | +$91.9M | 0.73% | 23 |
|
|
2014
Q1 | $117M | Sell |
1,657,474
-2,149,587
| -56% | -$170M | 0.32% | 87 |
|
|
2013
Q4 | $283M | Buy |
3,807,061
+945,000
| +33% | +$65.8M | 0.75% | 18 |
|
|
2013
Q3 | $217M | Sell |
2,862,061
-209,213
| -7% | -$16.6M | 0.62% | 32 |
|
|
2013
Q2 | $246M | Buy |
+3,071,274
| New | +$226M | 0.76% | 19 |
|
Other funds holding VRTX
VCM
VPM
Adage Capital Partners's VRTX Position: Q1 2026 in Review
Adage Capital Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 7.5% in Q1 2026, selling an estimated $9.55M and leaving 251,990 shares worth $113M. The position accounts for 0.17% of the portfolio, ranked #116.
Adage Capital Partners first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $291M in Q3 2014. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Adage Capital Partners held 251,990 shares of Vertex Pharmaceuticals worth $113M as of Q1 2026.
- Adage Capital Partners sold 20,484 Vertex Pharmaceuticals shares in Q1 2026, an estimated $9.55M.
- Vertex Pharmaceuticals made up 0.17% of Adage Capital Partners's portfolio in Q1 2026, its #116 holding.
- Adage Capital Partners first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Adage Capital Partners's Vertex Pharmaceuticals position peaked at $291M in Q3 2014.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.